Real-Time Genetic Repair

# Real-Time Genetic Repair **Entity class:** Concept or analytic term **Collections:** [[collections/Neurotech|Neurotech]] · [[collections/Consciousness Continuity|Consciousness Continuity]] ## Definition Real-time genetic repair is the prospective convergence of continuous molecular sensing, programmable editing, targeted delivery, and closed-loop verification. Present gene-editing and diagnostic systems establish components of that stack, but they do not yet establish autonomous, body-wide correction of genetic or epigenetic errors in real time. ## Relationships - **Collection route:** [[collections/Neurotech|Neurotech]]. - **Source context:** [[articles/Technologies for Consciousness Mapping and Transfer|Technologies for Consciousness Mapping and Transfer]] and [[articles/Mind Uploading and AI — The Host is Reusable and the Person is the Delta|Mind Uploading and AI — The Host is Reusable and the Person is the Delta]]. - **Inference provenance:** [[research/Research Inferences|Research Inferences]]. ## Research Inferences  These entries translate the forward-looking register in [[research/Research Inferences|Research Inferences]] into ordinary wiki prose. The tier labels apply to the inference, not automatically to every factual anchor inside it. The interpretive frame comes from [[articles/Technologies for Consciousness Mapping and Transfer|Technologies for Consciousness Mapping and Transfer]] and [[articles/Mind Uploading and AI — The Host is Reusable and the Person is the Delta|Mind Uploading and AI — The Host is Reusable and the Person is the Delta]]. Collection route: [[collections/Neurotech|Neurotech]]. ### Real-time genetic repair - **INF-0326 — Established.** An infant with CPS1 deficiency received a bespoke base-editing therapy designed for his individual mutation, dosed in February 2025 — the first personalized in vivo gene-editing treatment in a human. The unit of therapy became one patient, which is a structural break with every prior drug development model. - **Attractor routes:** [[wiki/cell-type-specific gene therapies and blood-based neuromodulation and monitoring|cell-type-specific gene therapies and blood-based neuromodulation and monitoring]] · [[wiki/RNA Editing|RNA Editing]] - **INF-0327 — Established.** A CHOP-and-Penn clinical-research pair designed, manufactured, and administered an individualized editing therapy inside a compressed timeline. The named individuals and their institutional pairing are the transfer mechanism by which bespoke editing became clinically real. - **Attractor routes:** [[wiki/RNA Editing|RNA Editing]] · [[wiki/cell-type-specific gene therapies and blood-based neuromodulation and monitoring|cell-type-specific gene therapies and blood-based neuromodulation and monitoring]] - **INF-0328 — Established.** The FDA's February 2026 draft framework permits first-in-human studies for individualized genetic therapies on preclinical proof-of-concept and allows new targets under a single application. Regulatory throughput, not editing chemistry, was the binding constraint, and this guidance directly relaxes it. - **Attractor routes:** [[wiki/genetic deviations|genetic deviations]] · [[wiki/cell-type-specific gene therapies and blood-based neuromodulation and monitoring|cell-type-specific gene therapies and blood-based neuromodulation and monitoring]] - **INF-0329 — Strongly indicated.** An umbrella-of-umbrellas protocol covering seven urea cycle disorders under one platform converts regulation from per-drug to per-method. Approving a method rather than a molecule is the change that makes n-of-one medicine economically possible. - **Attractor routes:** [[wiki/Medical AI|Medical AI]] · [[wiki/Therapeutic Governance|Therapeutic Governance]] - **INF-0330 — Established.** Prime editing writes specified sequences without double-strand breaks, making the edit a parameter rather than a redesign. When the therapeutic is a string, therapy development becomes a software-like activity with software-like iteration speed. - **Attractor routes:** [[wiki/RNA Editing|RNA Editing]] · [[wiki/cell-type-specific gene therapies and blood-based neuromodulation and monitoring|cell-type-specific gene therapies and blood-based neuromodulation and monitoring]] - **INF-0331 — Established.** Base editors change single nucleotides without breaks, addressing the largest class of pathogenic variants. Roughly 350 million people live with one of about 5,000 genetic diseases, many carrying mutations unique to an individual, which defines the addressable population of individualized editing. - **Attractor routes:** [[wiki/RNA Editing|RNA Editing]] · [[wiki/genetic deviations|genetic deviations]] - **INF-0332 — Established.** An IGI-led consortium received up to $27.7 million from ARPA-H to develop personalized in vivo editing for children with inborn errors. Dedicated federal funding for bespoke editing infrastructure signals that the state is building the pipeline, not merely permitting it. - **Attractor routes:** [[wiki/RNA Editing|RNA Editing]] · [[wiki/Epigenetic Modification|Epigenetic Modification]] - **INF-0333 — Established.** The field's argument that the FDA pathway converts an economically unworkable model into a scalable clinical reality is being made by the people who built the editing tools. Practitioner advocacy shaping regulatory design is the normal mechanism by which capability becomes permitted. - **Attractor routes:** [[wiki/Genomics|Genomics]] · [[wiki/RNA Editing|RNA Editing]] - **INF-0334 — Strongly indicated.** LNP delivery is non-viral and redosable, avoiding the anti-capsid immunity that limits AAV to a single administration. Redosability converts gene editing from a one-shot event into a repeatable clinical procedure, which is the property continuous genetic maintenance requires. - **Attractor routes:** [[wiki/Intranasal CNS Delivery|Intranasal CNS Delivery]] · [[wiki/Gene|Gene]] - **INF-0335 — Plausible.** If an edit can be delivered repeatedly and safely, the genome becomes a maintainable system rather than a fixed inheritance. Periodic correction of accumulated somatic damage is the logical endpoint, and it is an extension of an established delivery route rather than a new modality. - **Attractor routes:** [[wiki/genetic deviations|genetic deviations]] · [[wiki/Genome|Genome]] - **INF-0336 — Plausible.** Somatic mutation accumulation is a documented component of aging, and editing operates on exactly that class of change. A maintenance-editing program targeting high-burden tissues is the most direct translation of editing capability into longevity intervention. - **Attractor routes:** [[wiki/RNA Editing|RNA Editing]] · [[wiki/Epigenetic Modification|Epigenetic Modification]] - **INF-0337 — Established.** CRISPR-based epigenetic modulation changes gene expression without changing sequence, making the intervention tunable and reversible. Reversibility is what allows expression to be treated as a control variable rather than a permanent commitment. - **Attractor routes:** [[wiki/epigenetic and molecular deviations|epigenetic and molecular deviations]] · [[wiki/Epigenetic Modification|Epigenetic Modification]] - **INF-0338 — Plausible.** If expression of specific receptors or channels can be adjusted in a targeted population, the biophysical parameters of a circuit become externally settable. That is the mechanism by which a molecular interface could adjust the substrate rather than merely read it. - **Attractor routes:** [[wiki/epigenetic and molecular deviations|epigenetic and molecular deviations]] · [[wiki/Genome|Genome]] - **INF-0339 — Strongly indicated.** Delivering editing machinery across the blood-brain barrier is the single obstacle separating the editing toolkit from neurological application. Focused-ultrasound barrier opening and engineered capsids are two independent solutions already in clinical use. - **Attractor routes:** [[wiki/cell-type-specific gene therapies and blood-based neuromodulation and monitoring|cell-type-specific gene therapies and blood-based neuromodulation and monitoring]] · [[wiki/Gene|Gene]] - **INF-0340 — Established.** Base-editing treatment of Duchenne muscular dystrophy has maintained broadly stable motor function at one year in treated boys, and in vivo exon-targeting programs have entered clinical testing. Durable functional benefit from a single in vivo edit is now observed rather than projected. - **Attractor routes:** [[wiki/RNA Editing|RNA Editing]] · [[wiki/Genomics|Genomics]] - **INF-0341 — Established.** Alignment with the FDA on biomarker-based accelerated approval for a base-editing therapy shortens the evidence timeline for the whole modality. Biomarker endpoints are how a slow-moving disease becomes a fast-moving clinical program. - **Attractor routes:** [[wiki/Therapeutic Governance|Therapeutic Governance]] · [[wiki/cell-type-specific gene therapies and blood-based neuromodulation and monitoring|cell-type-specific gene therapies and blood-based neuromodulation and monitoring]] - **INF-0342 — Strongly indicated.** Off-target assessment is the central safety science of editing, and it improves with sequencing depth and prediction models. The safety bar is therefore falling in cost at the same rate as sequencing, which quietly expands what is approvable. - **Attractor routes:** [[wiki/RNA Editing|RNA Editing]] · [[wiki/Epigenetic Modification|Epigenetic Modification]] - **INF-0343 — Established.** A death following experimental base editing for a nonfatal neurodevelopmental disorder in China in 2026 marks the boundary between acceptable and unacceptable risk in non-life-threatening indications. Boundary events shape international regulatory posture more than successes do. - **Attractor routes:** [[wiki/RNA Editing|RNA Editing]] · [[wiki/Medical AI|Medical AI]] - **INF-0344 — Strongly indicated.** Contaminating plasmid sequences and disrupted vector genomes in the liver after AAV therapy demonstrate that manufacturing quality is a clinical variable. In individualized therapy, each patient's dose is a manufacturing run, which makes analytics the rate-limiting discipline. - **Attractor routes:** [[wiki/cell-type-specific gene therapies and blood-based neuromodulation and monitoring|cell-type-specific gene therapies and blood-based neuromodulation and monitoring]] · [[wiki/Genome|Genome]] - **INF-0345 — Established.** AI-engineered base editors are being distributed through access programs, meaning the editing enzyme itself is now a designed rather than discovered object. Designed enzymes shorten the loop between a target specification and a working tool to weeks. - **Attractor routes:** [[wiki/RNA Editing|RNA Editing]] · [[wiki/Regenerative Systems|Regenerative Systems]] - **INF-0346 — Analytic.** When the enzyme is designed, the guide is a string, and delivery is a formulation, the whole therapeutic becomes a computationally specified artifact. The iteration loop for medicine begins to resemble the iteration loop for software, which changes its improvement rate. - **Attractor routes:** [[wiki/Medical AI|Medical AI]] · [[wiki/RNA Editing|RNA Editing]] - **INF-0347 — Plausible.** A therapy specified as sequence data can be transmitted and synthesized near the patient rather than shipped. Manufacturing at the point of care is the logical endpoint of a fully digital therapeutic specification, and it makes distance irrelevant to treatment. - **Attractor routes:** [[wiki/Therapeutic Governance|Therapeutic Governance]] · [[wiki/cell-type-specific gene therapies and blood-based neuromodulation and monitoring|cell-type-specific gene therapies and blood-based neuromodulation and monitoring]] - **INF-0348 — Unresolved.** Somatic editing is broadly permitted while heritable editing is broadly prohibited, and the boundary depends on delivery specificity that improves continuously. Resolution will come through a jurisdictional divergence rather than an international agreement. - **Attractor routes:** [[wiki/RNA Editing|RNA Editing]] · [[wiki/Intranasal CNS Delivery|Intranasal CNS Delivery]] - **INF-0349 — Plausible.** Every editing capability approved for disease establishes a technique that applies equally to non-disease variation. Indication expansion is the ordinary life cycle of medical technology, and there is no mechanism in the approval system designed to stop it at the disease boundary. - **Attractor routes:** [[wiki/Medical AI|Medical AI]] · [[wiki/RNA Editing|RNA Editing]] - **INF-0350 — Plausible.** Combining continuous internal sensing with redosable editing yields a system that detects a genetic or expression deviation and corrects it on a maintenance schedule. That composite is the literal form of real-time genetic repair, and all three components exist independently today. - **Attractor routes:** [[wiki/genetic deviations|genetic deviations]] · [[wiki/epigenetic and molecular deviations|epigenetic and molecular deviations]]